Lipum has identified that BSSL has the potential to provide a unique way to treat chronic inflammations and is, yet, an unrecognized player in the pathophysiology and, thus, treatment of arthritis and most likely, other chronic inflammatory diseases. Namely, BSSL could be an attractive drug target to control inflammation via a novel mechanism of action.
Also, Lipum has shown that BSSL-deficient mice are protected from developing the disease in well-established animal models of autoimmune arthritis such as the pristane induced arthritis (PIA) model in rats, and in mice models collagen induced arthritis (CIA), collagen-antibody induced arthritis (CAIA) as well as dextran sulphate sodium (DSS) induced colitis, which is an IBD model.
The active ingredient will be a new biological drug, a unique monoclonal antibody targeting the BSSL molecule and inhibiting its action. The fact that it is an antibody, as are the TNFα inhibitors, will be an advantage when it comes to clinical implementation.
A cell line for Lipum´s candidate drug SOL-116 has been developed by our partner Abzena and production development in progress will lead to manufacturing of GMP material during 2021. In parallel, there will be toxicology studies and the clinical program will start during 2022, leading to a clinical proof of concept after Phase II in 2023.